2004 Press Releases Communiqués de presse

October 12, 2004 12 October, 2004

Pheromone Sciences Retains AGORA Investor Relations

September 1, 2004 1 September, 2004

Asset Sale of Fertility Monitor Closes; HealthWatchSystems, Inc. Now Owns Product Outright

June 28, 2004 28 June, 2004

Pheromone Sciences' Fertility Monitor Commercial Order Issued

March 5, 2004 5 March, 2004

Pheromone Sciences Sells Worldwide Marketing Rights To Its Fertilité-OV(tm) Fertility Monitor Technology

February 20, 2004 20 February, 2004

Pheromone Sciences Corp Announces CFO Change

February 5, 2004 5 February, 2004

Pheromone Sciences Corp Announces Private Placement of Convertible Debentures.

January 29, 2004 29 January, 2004

Pheromone Sciences Corp Provides Update

Press Releases from: Communiqués de presse de:

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - October 12, 2004 12 October, 2004

Pheromone Sciences Retains AGORA Investor Relations


TORONTO, ONTARIO, October 12, 2004 - Pheromone Sciences Corp. (TSX-V: PHS) (http://www.pheromonesciences.com) is pleased to announce it has retained the services of AGORA Investor Relations Corp. ("AGORA") (http://www.agoracom.com) to provide investor relations, communications and marketing services.

The objective of this agreement is to create effective communication between Pheromone, it's shareholders and the investment community through AGORA's powerful Internet based investor relations system. A customized and monitored on-line information & discussion centre will allow both the Company and AGORA to communicate with all investors simultaneously, anytime and in real-time, while providing shareholders with equal access and complete transparency to all investor relations communications. Effective immediately, shareholders can access the on-line discussion and information centre by going to http://www.agoracom.com and selecting the "Pheromone Sciences" Information and Discussion Forum.

In addition, AGORA will be fully responsible for creating, implementing and executing an investor relations strategy, including the drafting of all materials, responding to investor queries via the web and e-mail and maintaining the Company's shareholder database. This consolidation of investor relations activities will save management a considerable amount of time, effort and expense, allowing them to focus on core business operations, while significantly improving shareholder communications.

Finally, Pheromone will gain significant amounts of exposure to potential new shareholders as a result of AGORA's targeted small-cap audience at both its own proprietary financial portal and that of The AOL Small-Cap Centre. AGORA is the exclusive provider of all small-cap content to The AOL Small-Cap Centre.

Christopher Neuman, President and CEO commented "Following the successful sale of our Fertility Monitor technology on August 31, 2004 and the receipt of immediate cash proceeds, we are returning to our original mandate of seeking new opportunities in biotechnology. Armed with this success, the time is now right to put a strong emphasis on investor relations for the purposes of communicating our current intentions to both our shareholders and the investment community. AGORA fulfils our need to manage and execute an IR strategy in a cost efficient manner, while providing the management team with the ability to focus on executing our business plan. Our shareholders will benefit from the ability to now ask questions and receive answers at anytime and from anywhere, while receiving real-time and equal access to information as it becomes available." Mr. Neuman went on to say "shareholders will be very happy to know that significant cost savings already implemented by AGORA will reduce the overall cost of engaging the firm by more than 80%. This is a win-win relationship for Pheromone"

For all future Pheromone Sciences investor relations needs, investors are asked to visit http://www.agoracom.com and select the "Pheromone Sciences" forum. Alternatively, investors are asked to e- mail all questions and correspondence to PHS@agoracom.com

The terms of the agreement are as follows: Duration - 12 months. Monthly Cash Compensation - $2,500.00. Stock Options - 250,000 shares at $.15, vesting equally every quarter over the term of the agreement with a one year hold period. This agreement has been negotiated entirely at arm's length. At the present time, no individual affiliated with AGORA beneficially owns, controls or directs any shares of Pheromone. However, depending on market conditions, individuals affiliated with AGORA may in the future acquire, dispose of and/or beneficially own, control or direct shares of Pheromone. AGORA is located in Toronto, Ontario.

About AGORA Investor Relations Corp. http://www.agoracom.com

AGORA Investor Relations Corp. (AGORA) is North America's first and only Investor Relations firm delivering two-way investor relations and communications solely through monitored discussion forums and e-mail. The digital delivery of investor relations allows AGORA to deliver an end-to-end solution to small-cap companies at savings of 50-80% while providing superior communications, audience reach and 100% transparency.

AGORA has specialized in small-cap investor relations since 1997 and has represented over 30 small- cap companies, with over 18 companies currently under contract. By leveraging the power of its' high- traffic financial portal, (www.agoracom.com), The AOL Small Cap Center (www.aol.ca), superior investor relations discussion forum and unique e-mail communication tools, Agora maximizes the resonance of clients' message and image.

About Pheromone Sciences Corp. http://www.pheromonesciences.com

Pheromone Sciences Corp. is a biotechnology research and development company seeking new opportunities to leverage its resources.

CONTACT:

Christopher Neuman President and CEO (416) 861-9854 cneuman@pheromonesciences.com http://www.pheromonesciences.com

AGORA Investor Relations http://www.agoracom.com (Select "Pheromone Sciences") PHS@agoracom.com

THE TSX VENTURE EXCHANGE HAS NOT REVIEWED AND DOES NOT ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.



Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - September 01, 2004 1 September, 2004

Asset Sale of Fertility Monitor Closes; HealthWatchSystems, Inc. Now Owns Product Outright


Toronto, Ontario (September 1, 2004) -- Pheromone Sciences Corp. (TSX:PHS), a Toronto based biotech R & D company announces the completion of all the requirements to close the sale of its Fertility Monitor technology to HealthWatchSystems, Inc, a Sarasota, Florida based health care company.

As part of the transaction, HealthWatchSystems, Inc. has acquired the patents related to this technology. Pheromone has received $400,000. and will receive a graduated royalty on world wide sales of the fertility monitor and any related products stemming from this technology until the earlier of the expiration of the patents or 2014.

"The completion of this agreement represents a significant milestone for Pheromone Sciences, while contributing to the healthcare needs of couples seeking help in conception" stated Christopher Neuman, President and CEO of Pheromone.

Pheromone Sciences Corp. is a biotechnology research and development company seeking new opportunities to leverage its resources.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - June 28, 2004 28 June, 2004

Pheromone Sciences' Fertility Monitor Commercial Order Issued


Toronto, Ontario (June 28, 2004) -- Pheromone Sciences Corp. (TSX Venture: PHS), a Toronto based biotech company and the developer of the Fertilit�©-OV(tm) monitoring device is pleased to announce that HealthWatchSystems, the proposed purchaser of the Fertility Monitor technology, has placed its first commercial-scale order for the manufacture of Fertility Monitor units in anticipation of their launching the product throughout North America when all the preparations are complete.

This order when delivered will lead to royalty payments from HealthWatchSystems to Pheromone Sciences once the sales start.

In addition Ningxia St. Edenweiss will soon place their initial order for the product and commence its preliminary pre launch marketing activities, upon receipt of the marketing approval from the regulatory agencies of China. As previously announced, Ningxia St Edenweiss, is a public company whose shares are traded on China's Shenzhen Stock Exchange (symbol 000982) has obtained marketing and distribution rights for Pheromone's Fertilit�©- OV monitor in China, Hong Kong, Macao and Taiwan in August of 2003. Ningxia St Edenweiss is a manufacturing and marketing company with well-established relationships throughout the Chinese medical community.

"This manufacturing order is very gratifying to us all and it represents a significant milestone for both Pheromone Sciences and HEATHWATCHSYSTEMS INC.", stated Christopher Neuman, President and CEO of Pheromone.

The Fertilit�©-OV monitor is a FDA approved fertility cycle monitoring device for the consumer and professional medical market and provides a reliable "predictive" approach to natural, cycle-based family planning. The Fertilit�©-OV monitor is a non-invasive method of predicting the fertility window and ovulation date through the measurements of perspiration ion changes on the surface of the skin through a unique combination of bio- sensing and computer technologies These changes in female perspiration allow for the prediction of ovulation up to 4 days before the ovulation day.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human reproduction and sexuality.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - March 05, 2004 5 March, 2004

Pheromone Sciences Sells Worldwide Marketing Rights To Its Fertilité-OV(tm) Fertility Monitor Technology


Toronto, Ontario (May 5, 2004) -- Pheromone Sciences Corp. (TSX Venture: PHS), a Toronto based biotech company specializing in the field of ovulation detection, announces the signing of a definitive agreement pursuant to which HEALTHWATCHSYSTEMS, INC., a privately held company based in Sarasota, Florida will take over the worldwide marketing of Pheromone's proprietary technology, the Fertilit�©-OV�� fertility monitor and accompanying technology . As part of the transaction, HEALTHWATCHSYSTEMS will acquire the patents related to this technology. Pheromone will receive $500,000, payable on closing, and a graduated royalty on world wide sales of the fertility monitor and any related products stemming from this technology until the earlier of the expiration of the patents or 2014.

The transaction is subject to the approval of the TSX Venture Exchange and approval of Pheromone shareholders, which approval will be sought at Pheromone's annual and special meeting of shareholders to be held on August 25, 2004. Closing is anticipated to occur forthwith after the requisite approvals have been obtained.

Additionally, Pheromone has granted to HEALTHWATCHSYSTEMS a license, until closing, to make and sell the fertility monitor in North America for a non-refundable fee of $100,000, which will be credited toward the purchase price on closing. Pheromone will also receive a graduated royalty on sales in North America during the term of the license.

"The agreement represents a significant achievement for Pheromone Sciences while contributing to the health care needs of couples seeking help in conception", stated Dr. William Cochrane, Chairman of Pheromone. "We are confident that the management team of HEALTHWATCHSYSTEMS, INC. has the managerial resources to effectively market the product around the world."

About the Fertilit�©-OV

The Fertilit�©-OV monitor is a wristwatch styled fertility cycle monitoring device for the consumer and professional medical market and provides a reliable "predictive" approach to natural, cycle-based family planning. The Fertilit�©-OV monitor is a non-invasive method of predicting the fertility window and ovulation date through the measurements of perspiration ion changes on the surface of the skin through a unique combination of bio- sensing and computer technologies These changes in female perspiration allow for the prediction of ovulation up to 4 days before the ovulation day.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 20, 2004 20 February, 2004

Pheromone Sciences Corp Announces CFO Change


Toronto, Ontario -- February 20, 2004 -- Pheromone Sciences Corp. (TSX-V:PHS) today announced that it has accepted the resignation of Mr. Larry Cooper from his position of Chief Financial Officer of the company to pursue other interests effective February 20, 2004.

Mr. Florian Meyer MBA, CA has assumed the role of Chief Financial Officer effective today.

This transition is not expected to adversely affect the function of the company.



Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - February 05, 2004 5 February, 2004

Pheromone Sciences Corp Announces Private Placement of Convertible Debentures.


Toronto, Ontario -- February 5, 2004 -- Pheromone Sciences Corp. (TSX: PHS) today announced that it has received commitments for the purchase, on a private placement basis, of a principal amount of $400,000 of secured, non-interest bearing convertible debentures. Each $1.00 of this principal amount of Convertible Debenture is convertible, at the option of the holder, into 14.28 Common Shares and 10 Common Share Purchase Warrants. Each Warrant will entitle the holder to acquire one Common Share for $0.10 at any time prior to January 30, 2005. The debentures are convertible at any time until January 30, 2005.

Additionally, at the closing of this financing, the company will issue to Doug Marett, the inventor of the Fertility Monitor product, 12,500 units of the convertible debenture as compensation for the subordination of his patent rights in favor of the investors purchasing this convertible debenture.

Closing of this private placement is anticipated by February 16, 2004 and is subject to receipt of regulatory approval and definitive agreements.

Proceeds of the offering will be used to support the Company's commercialization and business development activities.

Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.

Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.

Share the news     Partagez les nouvelles

Email Facebook LinkedIn Twitter See direct link

Press Release Communiqué de presse - January 29, 2004 29 January, 2004

Pheromone Sciences Corp Provides Update


Toronto, Ontario -- January 29, 2004 -- Pheromone Sciences Corp. (TSX-V:PHS) today announced that it continues to evaluate its operational and financial options. As previously announced the company has scaled down all operations to provide maintenance working capital while it continues discussions with interested parties in the company's fertility monitor product. To this end, the company has laid off all employees. All severance requirements have been met.

The company has retained the services of its CEO and CFO on a contract basis, which includes a per diem rate upon completion of a successful financing and bonus provisions if a licensing agreement or other commercialization agreement is completed for its PSC Fertility Monitor or a sale or merger of the company is concluded.

Additionally, to permit the pursuit of various financing options, Doug Marett, the scientific founder of the company and the company's current CSO (Chief Scientific Officer), has subordinated the security he has over the company's patents in favor of any future participants in any future financing. To date, all patent maintenance fees have been paid.



Pheromone Sciences Corp. is a biotechnology and medical diagnostics device research and development company that focuses on commercializing technologies in the field of human and animal reproduction.



Statements contained in this press release, including those pertaining to scientific and clinical research, commercialization plans, strategic alliances, and intellectual property protection, other than statements of historical fact, are forward-looking statements subject to a number of uncertainties that could cause actual results to differ materially from statements made. The TSX Ventures Exchange has not reviewed and does not accept responsibility for the adequacy or the contents of this news release.